debate: is there a standard second line therapy for hcc? - regorafenib is a winner
Published 7 years ago • 468 plays • Length 11:18Download video MP4
Download video MP3
Similar videos
-
8:34
debate: is there a standard second line therapy for hcc? - no standard of therapy
-
12:54
debate 11: locally-advanced hepatocellular carcinoma (hcc) - ir-directed therapy
-
4:53
debate: salvage therapy for mcrc? - tas-102 followed by regorafenib
-
11:02
debate 3: salvage therapy for mcrc? - regorafenib
-
2:04
dr. bruix on regorafenib in second-line hcc
-
1:13:14
the great aids debate
-
59:08
diagnosis and management of liver cancer including transplant
-
1:01:11
covid-19 symposium: the sars-cov-2 pandemic | dr. stanley perlman
-
5:10
understanding the resorce data in second-line hcc
-
12:47
debate 11: locally-advanced hepatocellular carcinoma (hcc) - surgery is optimal
-
5:48
second-line therapy in advanced hcc
-
17:55
hepatocellular carcinoma: medical treatment
-
0:46
second-linetreatment for hcc
-
8:28
debate: optimal first-line therapy in unresectable hcc? - mki followed by immunotherapy
-
12:03
hepatocellular carcinoma debate - logoregional treatment first
-
9:06
debate: is there an optimal treatment for refractory colorectal cancer? - tas-102 or regorafenib
-
12:47
debate: salvage therapy for mcrc? regorafenib followed by tas-102
-
2:52
refine: a real-world analysis of regorafenib in patients with unresectable hcc
-
8:44
debate: optimal salvage therapy for refractory colon cancer? - tas102 or regorafenib
-
3:11
regorafenib in advanced hcc
-
1:15
regonext: 2l regorafenib in patients with unresectable hcc who have progressed on atezo-bev